MX2017002791A - Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. - Google Patents
Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.Info
- Publication number
- MX2017002791A MX2017002791A MX2017002791A MX2017002791A MX2017002791A MX 2017002791 A MX2017002791 A MX 2017002791A MX 2017002791 A MX2017002791 A MX 2017002791A MX 2017002791 A MX2017002791 A MX 2017002791A MX 2017002791 A MX2017002791 A MX 2017002791A
- Authority
- MX
- Mexico
- Prior art keywords
- mva
- recombinant
- relates
- vaccinia virus
- modified vaccinia
- Prior art date
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000711950 Filoviridae Species 0.000 title abstract 2
- 241001115402 Ebolavirus Species 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 241001115401 Marburgvirus Species 0.000 abstract 2
- 101710094648 Coat protein Proteins 0.000 abstract 1
- 208000007136 Filoviridae Infections Diseases 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045538P | 2014-09-03 | 2014-09-03 | |
| US201462055154P | 2014-09-25 | 2014-09-25 | |
| PCT/EP2015/070161 WO2016034678A2 (en) | 2014-09-03 | 2015-09-03 | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017002791A true MX2017002791A (es) | 2017-05-30 |
Family
ID=54145734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002791A MX2017002791A (es) | 2014-09-03 | 2015-09-03 | Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10576141B2 (OSRAM) |
| EP (1) | EP3188752A2 (OSRAM) |
| JP (2) | JP6823586B2 (OSRAM) |
| KR (2) | KR102736868B1 (OSRAM) |
| CN (2) | CN112972668A (OSRAM) |
| AU (2) | AU2015310909B2 (OSRAM) |
| CA (1) | CA2959105C (OSRAM) |
| IL (2) | IL250552B (OSRAM) |
| MX (1) | MX2017002791A (OSRAM) |
| MY (1) | MY193417A (OSRAM) |
| SG (2) | SG11201701506PA (OSRAM) |
| UA (1) | UA126848C2 (OSRAM) |
| WO (1) | WO2016034678A2 (OSRAM) |
| ZA (1) | ZA201701077B (OSRAM) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| WO2013032942A1 (en) | 2011-08-26 | 2013-03-07 | Yoshihiro Kawaoka | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| CN107075521B (zh) | 2014-11-04 | 2021-06-08 | 扬森疫苗与预防公司 | 治疗性hpv16疫苗 |
| EP3682821B1 (en) * | 2014-11-26 | 2022-05-11 | Neuravi Limited | A clot retrieval device for removing an occlusive clot from a blood vessel |
| WO2016115116A1 (en) * | 2015-01-12 | 2016-07-21 | Geovax, Inc. | Compositions and methods for generating an immune response to a hemorrhagic fever virus |
| EP3261669B1 (en) * | 2015-02-25 | 2022-08-03 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| CN116064669A (zh) | 2016-01-08 | 2023-05-05 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
| BR112018015696A2 (pt) | 2016-02-03 | 2018-12-26 | Geovax Inc | composições e métodos para gerar uma resposta imune para um flavivírus |
| EP3417056A1 (en) | 2016-02-19 | 2018-12-26 | Wisconsin Alumni Research Foundation (WARF) | Improved influenza b virus replication for vaccine development |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| CA3019199A1 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
| WO2017192418A1 (en) * | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| WO2018011768A1 (en) * | 2016-07-15 | 2018-01-18 | Janssen Vaccines And Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| AU2017345764A1 (en) * | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| CA3053812A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| IL319966A (en) | 2017-03-16 | 2025-05-01 | Alpine Immune Sciences Inc | CD80 Variant Immune Modulator Proteins and Uses Thereof |
| US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
| KR102658198B1 (ko) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
| AU2018269319A1 (en) | 2017-05-15 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2019018501A1 (en) * | 2017-07-18 | 2019-01-24 | Geovax Inc. | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| GB201716181D0 (en) * | 2017-10-04 | 2017-11-15 | Univ Cape Town | Recombinant mva with modified hiv-1 env |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| TW202500579A (zh) | 2017-10-18 | 2025-01-01 | 美商艾爾潘免疫科學有限公司 | 變異型icos 配位體免疫調節蛋白及相關組合物及方法 |
| JP2021500891A (ja) | 2017-10-25 | 2021-01-14 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス |
| US12297253B2 (en) | 2018-01-03 | 2025-05-13 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| CA3111273C (en) | 2018-09-06 | 2024-03-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| CN113453710A (zh) * | 2018-09-28 | 2021-09-28 | 剑桥大学的校长、教师和学者 | 疫苗和方法 |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| IL296250A (en) | 2020-03-12 | 2022-11-01 | Bavarian Nordic As | Compositions improving poxvirus stability |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN115819616B (zh) * | 2021-07-28 | 2025-04-11 | 江苏瑞科生物技术股份有限公司 | 一种基因重组vzv融合蛋白及其制备方法和应用 |
| WO2024188802A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
| CN120731268A (zh) | 2023-03-10 | 2025-09-30 | 巴法里安诺迪克有限公司 | 从鹌鹑细胞培养物产生痘病毒 |
| WO2024188801A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Use of quail cell lines for poxvirus production |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2776522C (en) * | 2001-10-01 | 2015-02-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| EP1586331B1 (en) * | 2001-10-01 | 2008-05-28 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Development of a preventive vaccine for filovirus infection in primates |
| US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
| US8101739B2 (en) * | 2004-09-27 | 2012-01-24 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| US20120251502A1 (en) * | 2008-10-24 | 2012-10-04 | The Government of the US as Represented by the Secretary of the Dept. of health | Human Ebola Virus Species and Compositions and Methods Thereof |
| EA024749B1 (ru) * | 2008-11-21 | 2016-10-31 | Бавариан Нордик А/С | Экспрессионный вектор со сниженным уровнем внутримолекулярной рекомбинации, содержащий гомологичные или гетерологичные нуклеотидные последовательности |
| EP2473525A4 (en) * | 2009-09-02 | 2013-08-21 | Us Army | MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS |
| EP2560680B1 (en) | 2010-04-16 | 2018-11-28 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Chimpanzee adenoviral vector-based filovirus vaccines |
| KR102351881B1 (ko) * | 2012-04-12 | 2022-01-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| GB201303406D0 (en) | 2013-02-26 | 2013-04-10 | Health Prot Agency | Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition |
-
2015
- 2015-09-03 WO PCT/EP2015/070161 patent/WO2016034678A2/en not_active Ceased
- 2015-09-03 JP JP2017510880A patent/JP6823586B2/ja active Active
- 2015-09-03 MX MX2017002791A patent/MX2017002791A/es unknown
- 2015-09-03 AU AU2015310909A patent/AU2015310909B2/en active Active
- 2015-09-03 MY MYPI2017700483A patent/MY193417A/en unknown
- 2015-09-03 US US15/508,851 patent/US10576141B2/en active Active
- 2015-09-03 CA CA2959105A patent/CA2959105C/en active Active
- 2015-09-03 EP EP15763853.7A patent/EP3188752A2/en active Pending
- 2015-09-03 SG SG11201701506PA patent/SG11201701506PA/en unknown
- 2015-09-03 CN CN202110238900.XA patent/CN112972668A/zh active Pending
- 2015-09-03 KR KR1020177006091A patent/KR102736868B1/ko active Active
- 2015-09-03 CN CN201580047328.1A patent/CN106999565B/zh active Active
- 2015-09-03 UA UAA201702987A patent/UA126848C2/uk unknown
- 2015-09-03 SG SG10201901735XA patent/SG10201901735XA/en unknown
- 2015-09-03 KR KR1020237030452A patent/KR102812180B1/ko active Active
-
2017
- 2017-02-12 IL IL250552A patent/IL250552B/en unknown
- 2017-02-13 ZA ZA2017/01077A patent/ZA201701077B/en unknown
-
2020
- 2020-02-27 US US16/802,805 patent/US11338030B2/en active Active
-
2021
- 2021-01-06 JP JP2021000975A patent/JP7113924B2/ja active Active
- 2021-07-28 AU AU2021209228A patent/AU2021209228A1/en not_active Abandoned
-
2022
- 2022-01-23 IL IL290052A patent/IL290052A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017002791A (es) | Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. | |
| ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
| MX2014006361A (es) | Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos. | |
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| MX2020013153A (es) | Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| MY173638A (en) | Parainfluenza virus 5 based vaccines | |
| PH12019500854A1 (en) | Recombinant vectors expressing antigens of avian influenza virus and uses thereof | |
| WO2012170765A3 (en) | Cmv glycoproteins and recombinant vectors | |
| WO2017066706A8 (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| MX2016009072A (es) | Fusion de antigenos micobacterianos heterooligomericos. | |
| MX2019000933A (es) | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). | |
| EA202091516A1 (ru) | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) | |
| EA202090628A1 (ru) | Система экспрессии paramyxoviridae | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| MX2020006471A (es) | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). | |
| MX390966B (es) | Vacunas contra el dengue | |
| PH12019500578A1 (en) | New promoters | |
| PH12012502301A1 (en) | Parapoxvirus vectors containing rabies virus antigen | |
| MX2017012389A (es) | Vacuna del virus de la parotiditis recombinante jeryl lynn2. | |
| PH12018502430A1 (en) | Vaccines | |
| MX2017009889A (es) | Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola. | |
| EA202193150A2 (ru) | Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
| WO2008118936A3 (en) | Method of elicting immune response with a modified mva viral hiv-1 vector | |
| PH12018500372A1 (en) | Fcv recombinant vaccines and uses thereof |